A Guideline-Driven Assessment of Need for Cardiovascular Disease Risk Intervention in Persons With Chronic Paraplegia

Archives of Physical Medicine and Rehabilitation

Volumn 88, Issue 6, 2007, Pages 751-757

  Nash, Mark S ^a   Mendez, Armando J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Lipids; Paraplegia; Rehabilitation; Risk

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MALE; METABOLIC SYNDROME X; PARAPLEGIA; PRACTICE GUIDELINE; RISK ASSESSMENT; SPINAL CORD LESION;

ACADEMIC MEDICAL CENTERS; ADULT; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PARAPLEGIA; PRACTICE GUIDELINES; RISK ASSESSMENT; SPINAL CORD INJURIES; TRAUMA SEVERITY INDICES;

EID: 34249338076     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2007.02.031     Document Type: Article

References (80)

1. Gerhart K.A., Bergstrom E., Charlifue S.W., Menter R.R., and Whiteneck G.G. Long-term spinal cord injury: functional changes over time. Arch Phys Med Rehabil 74 (1993) 1030-1034
2. Bauman W.A. The endocrine system. In: Whiteneck G.G., Charlifue S.W., and Gerhart K.A. (Eds). Aging with spinal cord injury (1993), Demos, New York 139-158
3. Samsa G.P., Patrick C.H., and Feussner J.R. Long-term survival of veterans with traumatic spinal cord injury. Arch Neurol 50 (1993) 909-914
4. Bauman W.A., Spungen A.M., Adkins R.H., and Kemp B.J. Metabolic and endocrine changes in persons aging with spinal cord injury. Assist Technol 11 (1999) 88-96
5. Bauman W.A., Raza M., Chayes Z., and Machac J. Tomographic thallium-201 myocardial perfusion imaging after intravenous dipyridamole in asymptomatic subjects with quadriplegia. Arch Phys Med Rehabil 74 (1993) 740-744
6. Groah S.L., and Menter R.R. Long-term cardiac ischemia leading to coronary artery bypass grafting in a tetraplegic patient. Arch Phys Med Rehabil 79 (1998) 1129-1132
7. Bauman W.A., Spungen A.M., Raza M., et al. Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. Mt Sinai J Med 59 (1992) 163-168
8. Groah S.L., Stiens S.A., Gittler M.S., Kirshblum S.C., and McKinley W.O. Spinal cord injury medicine. 5. Preserving wellness and independence of the aging patient with spinal cord injury: a primary care approach for the rehabilitation medicine specialist. Arch Phys Med Rehabil 83 3 Suppl 1 (2002) S82-S89 S90-8
9. Bauman W.A., Spungen A.M., Zhong Y.G., Rothstein J.L., Petry C., and Gordon S.K. Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia 30 (1992) 697-703
10. Brenes G., Dearwater S., Shapera R., LaPorte R.E., and Collins E. High density lipoprotein cholesterol concentrations in physically active and sedentary spinal cord injured patients. Arch Phys Med Rehabil 67 (1986) 445-450
11. Karlsson A.K., Attvall S., Jansson P.A., Sullivan L., and Lonnroth P. Influence of the sympathetic nervous system on insulin sensitivity and adipose tissue metabolism: a study in spinal cord-injured subjects. Metabolism 44 (1995) 52-58
12. Zlotolow S.P., Levy E., and Bauman W.A. The serum lipoprotein profile in veterans with paraplegia: the relationship to nutritional factors and body mass index. J Am Paraplegia Soc 15 (1992) 158-162
13. Maki K.C., Briones E.R., Langbein W.E., et al. Associations between serum lipids and indicators of adiposity in men with spinal cord injury. Paraplegia 33 (1995) 102-109
14. McGlinchey-Berroth R., Morrow L., Ahlquist M., Sarkarati M., and Minaker K.L. Late-life spinal cord injury and aging with a long term injury: characteristics of two emerging populations. J Spinal Cord Med 18 (1995) 183-193
15. Bauman W.A., Adkins R.H., Spungen A.M., et al. Is immobilization associated with an abnormal lipoprotein profile?. Observations from a diverse cohort. Spinal Cord 37 (1999) 485-493
16. Washburn R.A., and Figoni S.F. High density lipoprotein cholesterol in individuals with spinal cord injury: the potential role of physical activity. Spinal Cord 37 (1999) 685-695
17. Berg A., Halle M., Franz I., and Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Eur J Med Res 2 (1997) 259-264
18. Schaefer E.J., Lamon-Fava S., Ordovas J.M., et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 35 (1994) 871-882
19. Castelli W.P. Epidemiology of coronary heart disease: the Framingham study. Am J Med 76 (1984) 4-12
20. Castelli W.P., Anderson K., Wilson P.W., and Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2 (1992) 23-28
21. Smith Jr. S.C. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 120 3 Suppl 1 (2007) S3-S11
22. Nam B.H., Kannel W.B., and D'Agostino R.B. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol 97 (2006) 372-375
23. Chapman M.J. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 111 (2006) 893-908
24. Bowen P.H., and Guyton J.R. Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. Curr Atheroscler Rep 2 (2000) 58-63
25. Kwiterovich Jr. P.O. State-of-the-art update and review: clinical trials of lipid-lowering agents. Am J Cardiol 82 (1998) 3U-17U discussion 39U-41U
26. Guinchard-Foulon E., Rodriguez-Lafrasse C., and Rousson R. HDL-cholesterol: role of its dosage in the assessment of cardiovascular risk. Ann Biol Clin (Paris) 61 (2003) 549-556
27. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
28. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
29. McKenney J.M. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal. Pharmacotherapy 23 9 Pt 2 (2003) 26S-33S
30. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89 (1994) 1333-1445
31. Knopp R.H., and Mishell Jr. D.R. Cholesterol treatment recommendations for adults: highlights of the 1987 report from the National Cholesterol Education Program Adult Treatment Panel. Am J Obstet Gynecol 158 (1988) 1670-1674
32. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 48 (1988) 36-69
33. Rubinstein A. National Cholesterol Education Program. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 91 (1995) 908-909
34. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
36. Bauman W.A., and Spungen A.M. Metabolic changes in persons after spinal cord injury. Phys Med Rehabil Clin N Am 11 (2000) 109-140
37. Duckworth W.C., Solomon S.S., et al. Glucose intolerance due to insulin resistance in patients with spinal cord injuries. Diabetes 29 (1980) 906-910
38. Myers J., Lee M., and Kiratli J. Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil 86 (2007) 142-152
39. Kocina P. Body composition of spinal cord injured adults. Sports Med 23 (1997) 48-60
40. Nash M.S., Jacobs P.L., Mendez A.J., and Goldberg R.B. Circuit resistance training improves the atherogenic lipid profiles of persons with chronic paraplegia. J Spinal Cord Med 24 (2001) 2-9
41. Bachorik P.S., and Albers J.J. Precipitation methods for quantification of lipoproteins. Methods Enzymol 129 (1986) 78-100
42. Friedewald W., Levy R., and Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifugation. Clin Chem 18 (1972) 499
43. Dearwater S.R., LaPorte R.E., Robertson R.J., Brenes G., Adams L.L., and Becker D. Activity in the spinal cord-injured patient: an epidemiologic analysis of metabolic parameters. Med Sci Sports Exerc 18 (1986) 541-544
44. LaPorte R.E., Adams L.L., Savage D.D., Brenes G., Dearwater S., and Cook T. The spectrum of physical activity, cardiovascular disease and health: an epidemiologic perspective. Am J Epidemiol 120 (1984) 507-517
45. Bauman W.A., and Spungen A.M. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism 43 (1994) 749-756
46. Linn S., Fulwood R., Carroll M., et al. Serum total cholesterol: HDL cholesterol ratios in US white and black adults by selected demographic and socioeconomic variables (HANES II). Am J Public Health 81 (1991) 1038-1043
47. Demirel S., Demirel G., Tukek T., Erk O., and Yilmaz H. Risk factors for coronary heart disease in patients with spinal cord injury in Turkey. Spinal Cord 39 (2001) 134-138
48. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
49. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., and Lefant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
50. Spungen A.M., Adkins R.H., Stewart C.A., et al. Factors influencing body composition in persons with spinal cord injury: a cross-sectional study. J Appl Physiol 95 (2003) 2398-2407
51. Bostom A.G., Toner M.M., McArdle W.D., Montelione T., Brown C.D., and Stein R.A. Lipid and lipoprotein profiles relate to peak aerobic power in spinal cord injured men. Med Sci Sports Exerc 23 (1991) 409-414
52. Washburn R.A., and Figoni S.F. Physical activity and chronic cardiovascular disease prevention in spinal cord injury: a comprehensive literature review. Top Spinal Cord Inj Rehabil 3 (1998) 16-32
53. Bauman W.A., Kahn N.N., Grimm D.R., and Spungen A.M. Risk factors for atherogenesis and cardiovascular autonomic function in persons with spinal cord injury. Spinal Cord 37 (1999) 601-616
54. Pietrobelli A., Lee R.C., Capristo E., Deckelbaum R.J., and Heymsfield S.B. An independent, inverse association of high-density-lipoprotein-cholesterol concentration with nonadipose body mass. Am J Clin Nutr 69 (1999) 614-620
55. Kwiterovich Jr. P.O. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82 (1998) 13Q-21Q
56. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707-714
57. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl (1996) S11-S20
58. Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365-374
59. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
60. Sirtori C.R., Calabresi L., Marchioli R., and Rubins H.B. Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis 152 (2000) 1-8
61. Bloomfield Rubins H., Davenport J., et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103 (2001) 2828-2833
62. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
63. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
64. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18 (1997) 1569-1582
65. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 (2001) 554-572
66. Pyorala K., Lehto S., De Bacquer D., et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 47 (2004) 1257-1265
67. Bauman W.A., Raza M., Spungen A.M., and Machac J. Cardiac stress testing with thallium-201 imaging reveals silent ischemia in individuals with paraplegia. Arch Phys Med Rehabil 75 (1994) 946-950
68. Tousoulis D., Davies G., Ambrose J., Tentolouris C., Stefanadis C., and Toutouzas P. Effects of lipids on thrombotic mechanisms in atherosclerosis. Int J Cardiol 86 (2002) 239-247
69. Krum H., Howes L.G., Brown D.J., et al. Risk factors for cardiovascular disease in chronic spinal cord injury patients. Paraplegia 30 (1992) 381-388
70. Spungen A.M., Lesser M., Almenoff P.L., and Bauman W.A. Prevalence of cigarette smoking in a group of male veterans with chronic spinal cord injury. Mil Med 160 (1995) 308-311
71. Davies D.S., and McColl M.A. Lifestyle risks for three disease outcomes in spinal cord injury. Clin Rehabil 16 (2002) 96-108
72. Spungen A.M., Grimm D.R., Schilero G., et al. Relationship of respiratory symptoms with smoking status and pulmonary function in chronic spinal cord injury. J Spinal Cord Med 25 (2002) 23-27
73. Karlsson A.K. Insulin resistance and sympathetic function in high spinal cord injury. Spinal Cord 37 (1999) 494-500
74. Jones L.M., Goulding A., and Gerrard D.F. DEXA: a practical and accurate tool to demonstrate total and regional bone loss, lean tissue loss and fat mass gain in paraplegia. Spinal Cord 36 (1998) 637-640
75. Spungen A.M., Bauman W.A., Wang J., and Pierson Jr. R.N. Measurement of body fat in individuals with tetraplegia: a comparison of eight clinical methods. Paraplegia 33 (1995) 402-408
76. Weitzenkamp D.A., Jones R.H., Whiteneck G.G., and Young D.A. Ageing with spinal cord injury: cross-sectional and longitudinal effects. Spinal Cord 39 (2001) 301-309
77. Thomason S.S. Aging: a common denominator of disability. SCI Nurs 18 (2001) 3
78. Capoor J., and Stein A.B. Aging with spinal cord injury. Phys Med Rehabil Clin N Am 16 (2005) 129-161
79. Karlsson A.K., Elam M., Friberg P., Biering-Sorensen F., Sullivan L., and Lonnroth P. Regulation of lipolysis by the sympathetic nervous system: a microdialysis study in normal and spinal cord-injured subjects. Metabolism 46 (1997) 388-394
80. Levine A.M., Nash M.S., Green B.A., Shea J.D., and Aronica M.J. An examination of dietary intakes and nutritional status of chronic healthy spinal cord injured individuals. Paraplegia 30 (1992) 880-889